KALA BIO, Inc. — Investor Relations & Filings
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing innovative therapies for rare and severe eye diseases. The company utilizes its proprietary mesenchymal stem cell secretome (MSC-S) platform to create therapies with regenerative healing effects. Its lead product candidate, KPI-012, is a topical therapy in a Phase 2b clinical study for the treatment of persistent corneal epithelial defect (PCED), for which it has received Orphan Drug and Fast Track designations from the U.S. FDA. The pipeline also includes KPI-014, a preclinical, gene-agnostic intravitreal therapy being developed for inherited retinal degenerations. Following the sale of its commercial products in 2022, KALA BIO has concentrated its efforts on advancing its biologics pipeline for ophthalmic conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q | 2026-05-15 | English | |
| 10-K - KALA BIO, Inc. (0001479419) (Filer) | 2026-04-15 | English | |
| D - KALA BIO, Inc. (0001479419) (Filer) | 2026-03-17 | English | |
| 144 - KALA BIO, Inc. (0001479419) (Subject) | 2026-03-17 | English | |
| 8-K - KALA BIO, INC. (0001479419) (Filer) | 2026-03-04 | English | |
| 8-K - KALA BIO, INC. (0001479419) (Filer) | 2026-02-20 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46361127 | 10-Q | 2026-05-15 | English | ||
| 34609902 | 10-K - KALA BIO, Inc. (0001479419) (Filer) | 2026-04-15 | English | ||
| 32967766 | D - KALA BIO, Inc. (0001479419) (Filer) | 2026-03-17 | English | ||
| 32967403 | 144 - KALA BIO, Inc. (0001479419) (Subject) | 2026-03-17 | English | ||
| 32892479 | 8-K - KALA BIO, INC. (0001479419) (Filer) | 2026-03-04 | English | ||
| 32892478 | 8-K - KALA BIO, INC. (0001479419) (Filer) | 2026-02-20 | English | ||
| 30041686 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32892481 | S-3 - KALA BIO, INC. (0001479419) (Filer) | 2026-02-09 | English | ||
| 18339249 | 3 - KALA BIO, Inc. (0001479419) (Issuer) | 2026-02-09 | English | ||
| 18337689 | 3 - KALA BIO, Inc. (0001479419) (Issuer) | 2026-02-09 | English | ||
| 18331287 | 3 - KALA BIO, Inc. (0001479419) (Issuer) | 2026-02-09 | English | ||
| 18327819 | 3 - KALA BIO, Inc. (0001479419) (Issuer) | 2026-02-09 | English | ||
| 18326470 | 3 - KALA BIO, Inc. (0001479419) (Issuer) | 2026-02-09 | English | ||
| 30041682 | SCHEDULE 13D Filing | 2026-02-06 | English | ||
| 30041658 | 8-K Filing | 2026-02-05 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
|
Adaptogenics Health Corp.
Formulates and distributes functional mushroom and adaptoge…
|
ADPT | CA | Manufacturing |
|
Adastra Holdings
Manufacturer and supplier of ethnobotanical and processed c…
|
XTRX | CA | Manufacturing |
|
ADBIOTECH Co.,Ltd.
Develops IgY-based immune antibodies as alternatives to vac…
|
179530 | KR | Manufacturing |
|
ADC Therapeutics SA
Commercial-stage biotech developing antibody-drug conjugate…
|
ADCT | US | Manufacturing |
|
Addex Therapeutics Ltd.
Clinical-stage biopharma developing allosteric modulators f…
|
ADXN | CH | Manufacturing |
|
Adeshwar Meditex Limited
Manufacturer and exporter of medical disposables, surgical …
|
543309 | IN | Manufacturing |
|
ADIAL PHARMACEUTICALS, INC.
A clinical-stage biopharma developing genetically targeted …
|
ADIL | US | Manufacturing |
|
Adicet Bio, Inc.
Develops allogeneic gamma delta T cell therapies for cancer…
|
ACET | US | Manufacturing |
|
ADIM
Develops and manufactures human vaccines and biologics for …
|
4142 | TW | Manufacturing |
KALA BIO, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35091/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35091 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35091 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35091 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35091}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for KALA BIO, Inc. (id: 35091)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.